Evidence map›Paper›PMID 23893288›Full record

ArticleCellular & molecular biology letters2013

Molecular cloning and characterization of a novel anti-TLR9 intrabody.

Elisa Reimer, Stefan Somplatzki, Diana Zegenhagen, Svenja Hänel, Alina Fels, Thorsten Bollhorst, Ludger Grosse Hovest, Stefan Bauer, Carsten J Kirschning, Thomas Böldicke

Open access · goldAbstract read
In one paragraph

Article in Cellular & molecular biology letters, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Elisa ReimerDepartment of Gene Regulation and Differentiation, Helmholtz Centre for Infection Research, Inhoffenstraße 7, 38124 Braunschweig, Germany.
Stefan Somplatzki
Diana Zegenhagen
Svenja Hänel
Alina Fels
Thorsten Bollhorst
Ludger Grosse Hovest
Stefan Bauer
Carsten J Kirschning
Thomas Böldicke
Helmholtz Centre for Infection Research · DEInstitut für Medizinische Informatik, Biometrie und Epidemiologie · DEPhilipps University of Marburg · DEUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toll-like receptor 9 (TLR9) is a component of the innate immune system, which recognizes the DNA of both pathogens and hosts. Thus, it can drive autoimmune diseases. Intracellular antibodies expressed inside the ER block transitory protein functions by inhibiting the translocation of the protein from the ER to its subcellular destination. Here, we describe the construction and characterization of an anti-TLR9 ER intrabody (αT9ib). The respective single-chain Fv comprises the variable domains of the heavy and light chain of a monoclonal antibody (mAb; 5G5) towards human and murine TLR9. Co-expression of αT9ib and mouse TLR9 in HEK293 cells resulted in co-localization of both molecules with the ER marker calnexin. Co-immunoprecipitation of mouse TLR9 with αT9ib indicated that αT9ib interacts with its cognate antigen. The expression of αT9ib inhibited NF-κB-driven reporter gene activation upon CpG DNA challenge but not the activation of TLR3 or TLR4. Consequently, TLR9-driven TNFα production was inhibited in RAW264.7 macrophages upon transfection with the αT9ib expression plasmid. The αT9ib-encoding open reading frame was integrated into an adenoviral cosmid vector to produce the recombinant adenovirus (AdV)-αT9ib. Transduction with AdVαT9ib specifically inhibited TLR9-driven cellular TNFα release. These data strongly indicate that αT9ib is a very promising experimental tool to block TLR9 signaling.

Indexed as

Amino Acid SequenceAnimalsAntibodies, MonoclonalAntibody SpecificityAntigen-Antibody ReactionsBase SequenceCalnexinCell LineCloning, MolecularEndoplasmic ReticulumFlow CytometryHEK293 CellsHumansImmunoblottingLuciferasesMacrophagesAntibodies, MonoclonalCalnexinLuciferasesNF-kappa BSingle-Chain AntibodiesToll-Like Receptor 9Tumor Necrosis Factor-alpha

Identifiers

PMID23893288
PMCPMC6275677
OpenAlexW2027391580

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.